Christine Mikail Cvijic Sells 600 Shares of Neurogene (NASDAQ:NGNE) Stock

Posted by Geri Gentry on Jul 9th, 2026

Neurogene Inc. (NASDAQ:NGNE – Get Free Report) CFO Christine Mikail Cvijic sold 600 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $36.02, for a total value of $21,612.00. Following the sale, the chief financial officer owned 88,240 shares of the company’s stock, valued at approximately $3,178,404.80. This represents a 0.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

On Tuesday, July 7th, Christine Mikail Cvijic sold 4,200 shares of Neurogene stock. The stock was sold at an average price of $36.13, for a total value of $151,746.00.
On Thursday, July 2nd, Christine Mikail Cvijic sold 4,061 shares of Neurogene stock. The stock was sold at an average price of $34.82, for a total value of $141,404.02.
On Wednesday, July 1st, Christine Mikail Cvijic sold 739 shares of Neurogene stock. The stock was sold at an average price of $34.06, for a total value of $25,170.34.
On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The shares were sold at an average price of $31.25, for a total value of $300,000.00.

Neurogene Price Performance

Shares of NASDAQ NGNE opened at $38.24 on Thursday. The stock’s fifty day moving average price is $29.92 and its two-hundred day moving average price is $23.70. Neurogene Inc. has a one year low of $15.93 and a one year high of $39.30. The firm has a market cap of $604.19 million, a price-to-earnings ratio of -8.40 and a beta of 1.68.

Neurogene (NASDAQ:NGNE – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.09). On average, equities analysts anticipate that Neurogene Inc. will post -5.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Neurogene

A number of large investors have recently bought and sold shares of NGNE. BNP Paribas Financial Markets increased its holdings in Neurogene by 89.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after buying an additional 978 shares during the period. ADAR1 Capital Management LLC lifted its holdings in shares of Neurogene by 3.4% during the 3rd quarter. ADAR1 Capital Management LLC now owns 30,633 shares of the company’s stock worth $531,000 after acquiring an additional 1,008 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Neurogene by 17.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after acquiring an additional 1,059 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Neurogene by 12.8% in the first quarter. Bank of New York Mellon Corp now owns 26,043 shares of the company’s stock valued at $525,000 after acquiring an additional 2,950 shares during the last quarter. Finally, Daiwa Securities Group Inc. bought a new position in Neurogene in the fourth quarter valued at approximately $66,000. 52.37% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on NGNE shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a report on Tuesday, April 21st. Canaccord Genuity Group lowered their target price on shares of Neurogene to $180.00 and set a “buy” rating on the stock in a report on Monday, April 6th. HC Wainwright reiterated a “buy” rating and issued a $70.00 price target on shares of Neurogene in a research report on Tuesday, June 9th. Rodman & Renshaw assumed coverage on Neurogene in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $70.00 price target for the company. Finally, Guggenheim initiated coverage on Neurogene in a research report on Tuesday, April 28th. They set a “buy” rating and a $69.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $84.83.

View Our Latest Report on Neurogene

About Neurogene

(Get Free Report)

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.